Fospropofol disodium injection as a sedative reduces hypoxemia and postinduction hypotension in patients undergoing painless gastrointestinal endoscopy: A prospective, randomized, controlled, multicenter clinical trial
This prospective, randomized, multicenter trial demonstrates that fospropofol disodium injection offers superior respiratory and circulatory stability with reduced rates of hypoxemia, postinduction hypotension, and injection pain compared to propofol for sedation during painless gastrointestinal endoscopy, despite resulting in longer induction times and less effective control of patient movement.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of people undergo examinations of their digestive tract using a flexible tube equipped with a camera. While these procedures are vital for detecting disease, the experience can be uncomfortable or even painful. To solve this, doctors often use sedation to help patients relax and remain still. The most common drug used for this purpose is propofol, a medication that acts quickly to induce a state of deep sleep. However, this speed comes with a trade-off. Because propofol works so fast, it can sometimes cause a sudden drop in blood pressure or a temporary struggle to breathe, particularly in older adults or those with other health concerns. These side effects, known as post-induction hypotension and hypoxemia, require doctors to intervene quickly to keep the patient safe.
Researchers have been looking for a way to keep the benefits of propofol while reducing these risks. A promising alternative is a drug called fospropofol disodium. Think of this medication as a slow-release version of the standard drug. Instead of entering the bloodstream ready to work immediately, it is a "prodrug," meaning it is an inactive form that the body must slowly convert into the active drug. This gradual conversion is designed to create a smoother, more stable effect on the heart and lungs. A new study conducted across five hospitals in China set out to test whether this slower approach actually makes gastrointestinal endoscopy safer and more comfortable for patients.
The researchers recruited 426 adults, all between the ages of 50 and 65, who were scheduled for elective digestive tract examinations. These patients were generally healthy, with no severe heart or lung conditions. They were randomly divided into two groups. One group received the standard propofol, while the other received the new fospropofol disodium. To ensure a fair comparison, every patient also received a small dose of a pain-relieving medication called sufentanil before the sedative was given. The medical team then monitored the patients closely, tracking their blood pressure, oxygen levels, and how deeply they were sedated throughout the procedure.
The results showed a clear difference in how the two drugs affected the body's vital signs. Patients who received the standard propofol were significantly more likely to experience a sharp drop in blood pressure shortly after the drug was given. About 15 percent of these patients required medical attention to stabilize their blood pressure. In contrast, only about 4 percent of the patients receiving fospropofol disodium experienced this drop. Similarly, the risk of low oxygen levels was much higher in the standard group, affecting roughly 17 percent of patients, compared to just 4 percent in the new drug group. The new drug also proved gentler on the veins; while nearly 17 percent of patients in the standard group felt a burning sensation at the injection site, this occurred in only about 1 percent of those receiving fospropofol disodium.
However, the study also highlighted a distinct trade-off. Because the new drug releases its active ingredient slowly, it took longer to work. Patients in the fospropofol group waited an average of over four minutes to reach the desired level of sedation, whereas those in the standard group were sedated in less than two minutes. This delay meant that the new drug was less effective at keeping patients perfectly still during the first few minutes of the procedure. About 13 percent of patients in the new drug group moved occasionally or frequently, compared to none in the standard group. Additionally, a small number of patients in the new drug group reported a tingling sensation or itching, primarily in the buttock area, which did not occur with the standard drug.
Despite these differences in speed and movement control, the overall experience for the patients remained positive. The time it took for patients to wake up and leave the recovery area was actually slightly shorter for those who received the new drug. More importantly, the patients' satisfaction scores were nearly identical between the two groups. This suggests that while the standard drug works faster, the new drug's ability to protect against dangerous drops in blood pressure and oxygen levels, combined with the lack of injection pain, made the procedure feel just as good to the patients. The study concludes that fospropofol disodium offers a safer profile for the heart and lungs, making it a viable option for sedation, particularly for patients where stability is more critical than the speed of onset.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.